10x Genomics, Inc. has grown revenue 2.8% a year over three years and 8.7% a year over five. Revenue growth, 3-year annual rate: +2.8% (Health Information Services median +10%). Revenue growth, 5-year rate: +8.7%, growth has slowed since the five-year average. Years of annual history on file: 9, FY2017 to FY2025, as filed.

TXG10x Genomics, Inc.

Healthcare

$80.64+518% 1Y

$80.64

$11.3452 weeks$97.82

Is it growing?

Mixed

Neither accelerating nor breaking down: operating margin widening (+2.0 points), but revenue shrinking (−4% year on year).

1 good, 1 to watch, 1 without data

Revenue trend−4% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +9% a year.

Margin direction+2.0 points operating

Trailing-twelve-month operating margin, -14.4% now against -16.4% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

Revenue growth, 3 yearsmiddle of the market

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is TXG growing?

10x Genomics, Inc. has grown revenue 2.8% a year over three years and 8.7% a year over five.

+2.8%

Revenue growth, 3-year annual rate · Health Information Services median +10% · growing slowly · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +8.7%
Revenue growth, 5-year rate · +2.8% over three · growth has slowed since the five-year average
Years of annual history on file: 9
Years of annual history on file · FY2017 to FY2025, as filed

Details›